XOMA Corporation (XOMAP)

XOMA Corporation at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

XOMA Corporation (XOMAP) is a Biotechnology company based in US with a market capitalization of $301.3M. Revenue grew 83.1% year-over-year and the company generated $2.9M in free cash flow. This page tracks XOMAP's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 13 employees · IPO Dec 16, 2020

Valuation

Valuation & price

$24.98as of Jul 25, 2026· -8.3% vs 52w high

14.2

P/E ratio

Latest-FY diluted EPS

2.90

P/B ratio

Market cap ÷ book equity

1.13%

Dividend yield

Latest fiscal year

Price — last 12 months

$27.25$26.11$24.96Jul 25Jan 26Jul 26
$24.9652-week range$27.25
Loading valuation history…

Fundamentals

Key fundamentals

$301.3M

Market cap

83.1%

Revenue growth (YoY)

94.3%

Gross margin

$2.9M

Free cash flow (USD)

$48.6M

Net debt

53.7%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

20162025

$5.6M$52.1M

Free cash flow by year

20162025

-$33.7M$2.9M

Gross margin by year

20212025

99.5%94.3%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 12, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventJul 14, 2026Filing

    Merger Completion

  • 8-K eventJun 12, 2026Filing

    Preferred Stock Redemption

  • 8-K eventMay 22, 2026Filing

    Incentive Plan Amended

  • 8-K eventMay 18, 2026Filing

    Merger Agreement Amendment

  • Quarterly reportMay 12, 2026Filing

    10-Q Filed

  • 8-K eventApr 27, 2026Filing

    Merger Agreement

  • 8-K eventApr 27, 2026Filing

    Acquisition Completed

Questions

Frequently asked questions

What is XOMA Corporation's market cap?

XOMA Corporation (XOMAP) has a market capitalization of $301.3M.

What is XOMAP's P/E ratio?

XOMAP trades at a price-to-earnings ratio of 14.2, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is XOMAP's price-to-book (P/B) ratio?

XOMAP trades at 2.90 times book value per share.

Does XOMA Corporation pay a dividend?

Yes — XOMAP paid roughly $0.30 per share in dividends over its latest fiscal year, a yield of about 1.13%.

Are insiders buying XOMAP stock?

SEC Form 4 filings show no open-market insider buys at XOMA Corporation in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.